{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T13:44:57Z","timestamp":1774619097049,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,9]],"date-time":"2021-01-09T00:00:00Z","timestamp":1610150400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,9]],"date-time":"2021-01-09T00:00:00Z","timestamp":1610150400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Res Ther"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Pediatric tuberculosis (TB), human immunodeficiency virus (HIV), and TB-HIV co-infection are health problems with evidence-based diagnostic and treatment algorithms that can reduce morbidity and mortality. Implementation and operational barriers affect adherence to guidelines in many resource-constrained settings, negatively affecting patient outcomes. This study aimed to assess performance in the pediatric HIV and TB care cascades in Mozambique.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A retrospective analysis of routine PEPFAR site-level HIV and TB data from 2012 to 2016 was performed. Patients 0\u201314\u00a0years of age were included. Descriptive statistics were used to report trends in TB and HIV indicators. Linear regression was done to assess associations of site-level variables with performance in the pediatric TB and HIV care cascades using 2016 data.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Routine HIV testing and cotrimoxazole initiation for co-infected children in the TB program were nearly optimal at 99% and 96% in 2016, respectively. Antiretroviral therapy (ART) initiation was lower at 87%, but steadily improved from 2012 to 2016. From the HIV program, TB screening at the last consultation rose steadily over the study period, reaching 82% in 2016. The percentage of newly enrolled children who received either TB treatment or isoniazid preventive treatment (IPT) also steadily improved in all provinces, but in 2016 was only at 42% nationally. Larger volume sites were significantly more likely to complete the pediatric HIV and TB care cascades in 2016 (p value range 0.05 to\u2009&lt;\u20090.001).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Mozambique has made significant strides in improving the pediatric care cascades for children with TB and HIV, but there were missed opportunities for TB diagnosis and prevention, with IPT utilization being particularly problematic. Strengthened TB\/HIV programming that continues to focus on pediatric ART scale-up while improving delivery of TB preventive therapy, either with IPT or newer rifapentine-based regimens for age-eligible children, is needed.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12981-020-00325-9","type":"journal-article","created":{"date-parts":[[2021,1,9]],"date-time":"2021-01-09T10:06:49Z","timestamp":1610186809000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Integrated TB and HIV care for Mozambican children: temporal trends, site-level determinants of performance, and recommendations for improved TB preventive treatment"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6304-2262","authenticated-orcid":false,"given":"W. Chris","family":"Buck","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanh","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana","family":"Siapka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lopa","family":"Basu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Greenberg Cowan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria In\u00eas","family":"De Deus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan","family":"Gleason","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ferreira","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Xavier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedita","family":"Jose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Crim\u00e9nia","family":"Muthemba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatriz","family":"Simione","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Kerndt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,9]]},"reference":[{"key":"325_CR1","unstructured":"Data AIDS. Geneva: UNAIDS; 2016."},{"key":"325_CR2","unstructured":"Relat\u00f3rio Anual 2016; Relat\u00f3rio Anual das Actividades Relacionadas ao HIV\/SIDA. Maputo, Mozambique: Minist\u00e9rio da Sa\u00fade, Mo\u00e7ambique; 2016."},{"key":"325_CR3","unstructured":"Global Tuberculosis Report. Geneva. Switzerland: World Health Organization; 2017."},{"key":"325_CR4","unstructured":"Relatorio de Actividades Desenvolvidas durante o Ano de 2017 (TB). Maputo, Mozambique: Minist\u00e9rio da Sa\u00fade, Mo\u00e7ambique; 2017."},{"issue":"3","key":"325_CR5","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.prrv.2004.04.006","volume":"5","author":"S Swaminathan","year":"2004","unstructured":"Swaminathan S. Tuberculosis in HIV-infected children. Paediatr Respir Rev. 2004;5(3):225\u201330.","journal-title":"Paediatr Respir Rev"},{"issue":"3","key":"325_CR6","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.idc.2010.04.004","volume":"24","author":"BJ Marais","year":"2010","unstructured":"Marais BJ, Schaaf HS. Childhood tuberculosis: an emerging and previously neglected problem. Infect Dis Clin North Am. 2010;24(3):727\u201349.","journal-title":"Infect Dis Clin North Am"},{"issue":"2","key":"325_CR7","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.ccm.2005.02.010","volume":"26","author":"K Feja","year":"2005","unstructured":"Feja K, Saiman L. Tuberculosis in children. Clin Chest Med. 2005;26(2):295\u2013312.","journal-title":"Clin Chest Med."},{"key":"325_CR8","volume-title":"Maputo","author":"M de Tuberculose","year":"2013","unstructured":"de Tuberculose M, Mo\u00e7ambique I. Maputo. Mozambique: Minist\u00e9rio da Sa\u00fade, Mo\u00e7ambique; 2013."},{"key":"325_CR9","unstructured":"Guia de Tratamento Antiretroviral e Infec\u00e7\u00f5es Oportunistas no Adulto, Adolescente, Gr\u00e1vida e Crian\u00e7a. Maputo, Mozambique: Minist\u00e9rio da Sa\u00fade, Mo\u00e7ambique; 2014."},{"key":"325_CR10","unstructured":"Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: Recommendations for a public health approach. Geneva: World Health Organization; 2013."},{"key":"325_CR11","unstructured":"Guidance for national tuberculosis programmes on the management of tuberculosis in children. Geneva: World Health Organization; 2014."},{"key":"325_CR12","unstructured":"Latent tuberculosis infection. updated and consolidated guidelines for programmatic management. Geneva: World Health Organization; 2018."},{"key":"325_CR13","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12916-016-0593-7","volume":"14","author":"AM Crook","year":"2016","unstructured":"Crook AM, Turkova A, Musiime V, Bwakura-Dangarembizi M, Bakeera-Kitaka S, Nahirya-Ntege P, et al. Tuberculosis incidence is high in HIV-infected African children but is reduced by co-trimoxazole and time on antiretroviral therapy. BMC Med. 2016;14:50.","journal-title":"BMC Med"},{"issue":"10","key":"325_CR14","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.5588\/ijtld.16.0060","volume":"20","author":"LA Enane","year":"2016","unstructured":"Enane LA, Lowenthal ED, Arscott-Mills T, Matlhare M, Smallcomb LS, Kgwaadira B, et al. Loss to follow-up among adolescents with tuberculosis in Gaborone, Botswana. Int J Tuber Lung Dis. 2016;20(10):1320\u20135.","journal-title":"Int J Tuber Lung Dis"},{"issue":"11","key":"325_CR15","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.5588\/ijtld.13.0030","volume":"17","author":"WC Buck","year":"2013","unstructured":"Buck WC, Olson D, Kabue MM, Ahmed S, Nchama LK, Munthali A, et al. Risk factors for mortality in Malawian children with human immunodeficiency virus and tuberculosis co-infection. Int J Tuber Lung Dis. 2013;17(11):1389\u201395.","journal-title":"Int J Tuber Lung Dis"},{"issue":"7","key":"325_CR16","doi-asserted-by":"publisher","first-page":"e100039","DOI":"10.1371\/journal.pone.0100039","volume":"9","author":"B Ojikutu","year":"2014","unstructured":"Ojikutu B, Higgins-Biddle M, Greeson D, Phelps BR, Amzel A, Okechukwu E, et al. The association between quality of HIV care, loss to follow-up and mortality in pediatric and adolescent patients receiving antiretroviral therapy in Nigeria. PLoS ONE. 2014;9(7):e100039.","journal-title":"PLoS ONE"},{"issue":"5","key":"325_CR17","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1097\/COH.0000000000000303","volume":"11","author":"MA Davies","year":"2016","unstructured":"Davies MA, Gibb D, Turkova A. Survival of HIV-1 vertically infected children. Curr Opin HIV AIDS. 2016;11(5):455\u201364.","journal-title":"Curr Opin HIV AIDS"},{"issue":"Suppl 1","key":"325_CR18","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1097\/COH.0000000000000262","volume":"11","author":"M Diese","year":"2016","unstructured":"Diese M, Shrestha L, Pradhan B, Singh D, Raaijmakers H, Kisesa A, et al. Bottlenecks and opportunities for delivering integrated pediatric HIV services in Nepal. Curr Opin HIV AIDS. 2016;11(Suppl 1):S21\u20139.","journal-title":"Curr Opin HIV AIDS"},{"issue":"Suppl 2","key":"325_CR19","doi-asserted-by":"publisher","first-page":"S235","DOI":"10.1097\/QAD.0000000000000099","volume":"27","author":"S Ahmed","year":"2013","unstructured":"Ahmed S, Kim MH, Sugandhi N, Phelps BR, Sabelli R, Diallo MO, et al. Beyond early infant diagnosis: case finding strategies for identification of HIV-infected infants and children. AIDS (London, England). 2013;27(Suppl 2):S235\u201345.","journal-title":"AIDS (London, England)"},{"issue":"Suppl 2","key":"325_CR20","doi-asserted-by":"publisher","first-page":"S207","DOI":"10.1097\/QAD.0000000000000095","volume":"27","author":"BR Phelps","year":"2013","unstructured":"Phelps BR, Ahmed S, Amzel A, Diallo MO, Jacobs T, Kellerman SE, et al. Linkage, initiation and retention of children in the antiretroviral therapy cascade: an overview. AIDS (London, England). 2013;27(Suppl 2):S207\u201313.","journal-title":"AIDS (London, England)"},{"issue":"4","key":"325_CR21","doi-asserted-by":"publisher","first-page":"253","DOI":"10.2471\/BLT.09.066522","volume":"88","author":"AA Date","year":"2010","unstructured":"Date AA, Vitoria M, Granich R, Banda M, Fox MY, Gilks C. Implementation of co-trimoxazole prophylaxis and isoniazid preventive therapy for people living with HIV. Bull World Health Organ. 2010;88(4):253\u20139.","journal-title":"Bull World Health Organ"},{"issue":"Suppl 5","key":"325_CR22","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1097\/01.aids.0000391021.18284.12","volume":"24","author":"R Lester","year":"2010","unstructured":"Lester R, Hamilton R, Charalambous S, Dwadwa T, Chandler C, Churchyard GJ, et al. Barriers to implementation of isoniazid preventive therapy in HIV clinics: a qualitative study. AIDS (London, England). 2010;24(Suppl 5):S45\u20138.","journal-title":"AIDS (London, England)"},{"issue":"2","key":"325_CR23","doi-asserted-by":"publisher","first-page":"105","DOI":"10.5501\/wjv.v4.i2.105","volume":"4","author":"C Akolo","year":"2015","unstructured":"Akolo C, Bada F, Okpokoro E, Nwanne O, Iziduh S, Usoroh E, et al. Debunking the myths perpetuating low implementation of isoniazid preventive therapy amongst human immunodeficiency virus-infected persons. World J Virol. 2015;4(2):105\u201312.","journal-title":"World J Virol"},{"issue":"7","key":"325_CR24","doi-asserted-by":"publisher","first-page":"903","DOI":"10.5588\/ijtld.11.0722","volume":"16","author":"JC Chehab","year":"2012","unstructured":"Chehab JC, Vilakazi-Nhlapo K, Vranken P, Peters A, Klausner JD. Survey of isoniazid preventive therapy in South Africa, 2011. Int J Tuber Lung Dis. 2012;16(7):903\u20137.","journal-title":"Int J Tuber Lung Dis"},{"issue":"3","key":"325_CR25","doi-asserted-by":"publisher","first-page":"174","DOI":"10.7196\/SAMJ.7968","volume":"104","author":"R Wood","year":"2014","unstructured":"Wood R, Bekker LG. Isoniazid preventive therapy for tuberculosis in South Africa: an assessment of the local evidence base. SAMJ South Afr Med J. 2014;104(3):174\u20137.","journal-title":"SAMJ South Afr Med J"},{"issue":"6","key":"325_CR26","doi-asserted-by":"publisher","first-page":"596","DOI":"10.5588\/ijtld.17.0758","volume":"22","author":"I Pathmanathan","year":"2018","unstructured":"Pathmanathan I, Ahmedov S, Pevzner E, Anyalechi G, Modi S, Kirking H, et al. TB preventive therapy for people living with HIV: key considerations for scale-up in resource-limited settings. Int J Tuber Lung Dis. 2018;22(6):596\u2013605.","journal-title":"Int J Tuber Lung Dis"},{"issue":"Suppl 5","key":"325_CR27","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1097\/01.aids.0000391023.03037.1f","volume":"24","author":"H Getahun","year":"2010","unstructured":"Getahun H, Granich R, Sculier D, Gunneberg C, Blanc L, Nunn P, et al. Implementation of isoniazid preventive therapy for people living with HIV worldwide: barriers and solutions. AIDS (London, England). 2010;24(Suppl 5):S57-65.","journal-title":"AIDS (London, England)"},{"issue":"8","key":"325_CR28","first-page":"927","volume":"13","author":"N Ait-Khaled","year":"2009","unstructured":"Ait-Khaled N, Alarcon E, Bissell K, Boillot F, Caminero JA, Chiang CY, et al. Isoniazid preventive therapy for people living with HIV: public health challenges and implementation issues. Int J Tuber Lung Dis. 2009;13(8):927\u201335.","journal-title":"Int J Tuber Lung Dis"},{"issue":"1","key":"325_CR29","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1097\/QAI.0000000000000806","volume":"71","author":"P Costenaro","year":"2016","unstructured":"Costenaro P, Massavon W, Lundin R, Nabachwa SM, Fregonese F, Morelli E, et al. Implementation and Operational Research: Implementation of the WHO 2011 Recommendations for Isoniazid Preventive Therapy (IPT) in Children Living With HIV\/AIDS: A Ugandan Experience. J Acq Immun Defic Syndr. 2016;71(1):e1-8.","journal-title":"J Acq Immun Defic Syndr."},{"issue":"3","key":"325_CR30","doi-asserted-by":"publisher","first-page":"204","DOI":"10.5588\/pha.13.0013","volume":"3","author":"EO Masini","year":"2013","unstructured":"Masini EO, Sitienei J, Weyeinga H. Outcomes of isoniazid prophylaxis among HIV-infected children attending routine HIV care in Kenya. Public health action. 2013;3(3):204\u20138.","journal-title":"Public health action"},{"issue":"1","key":"325_CR31","doi-asserted-by":"publisher","first-page":"55","DOI":"10.5588\/pha.16.0102","volume":"7","author":"KC Takarinda","year":"2017","unstructured":"Takarinda KC, Choto RC, Harries AD, Mutasa-Apollo T, Chakanyuka-Musanhu C. Routine implementation of isoniazid preventive therapy in HIV-infected patients in seven pilot sites in Zimbabwe. Public Health Action. 2017;7(1):55\u201360.","journal-title":"Public Health Action"},{"issue":"12","key":"325_CR32","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.5588\/ijtld.18.0168","volume":"22","author":"Y Hamada","year":"2018","unstructured":"Hamada Y, Ford N, Schenkel K, Getahun H. Three-month weekly rifapentine plus isoniazid for tuberculosis preventive treatment: a systematic review. Int J Tuberc Lung Dis. 2018;22(12):1422\u20138.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"11","key":"325_CR33","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1056\/NEJMoa1806808","volume":"380","author":"S Swindells","year":"2019","unstructured":"Swindells S, Ramchandani R, Gupta A, Benson CA, Leon-Cruz J, Mwelase N, et al. One month of Rifapentine plus isoniazid to prevent HIV-related tuberculosis. N Engl J Med. 2019;380(11):1001\u201311.","journal-title":"N Engl J Med"}],"container-title":["AIDS Research and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-020-00325-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12981-020-00325-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-020-00325-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,9]],"date-time":"2021-01-09T22:12:37Z","timestamp":1610230357000},"score":1,"resource":{"primary":{"URL":"https:\/\/aidsrestherapy.biomedcentral.com\/articles\/10.1186\/s12981-020-00325-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,9]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["325"],"URL":"https:\/\/doi.org\/10.1186\/s12981-020-00325-9","relation":{},"ISSN":["1742-6405"],"issn-type":[{"value":"1742-6405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,9]]},"assertion":[{"value":"13 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Use of routine, anonymized data for this study was approved by the Mozambican Ethics Committee and the Center for Global Health Science Office at the Centers for Disease Control and Prevention. Informed consent was not required.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3"}}